Optus Pharmaceutical Co Ltd
KOSDAQ:131030
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Optus Pharmaceutical Co Ltd
Cost of Revenue
Optus Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Optus Pharmaceutical Co Ltd
KOSDAQ:131030
|
Cost of Revenue
-₩39B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-10%
|
|
|
Suheung Co Ltd
KRX:008490
|
Cost of Revenue
-₩592.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
|
SD Biosensor Inc
KRX:137310
|
Cost of Revenue
-₩355.2B
|
CAGR 3-Years
36%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Cost of Revenue
-₩23.8B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Inc
KOSDAQ:028300
|
Cost of Revenue
-₩56.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-6%
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Cost of Revenue
-₩99.4B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
Optus Pharmaceutical Co Ltd
Glance View
OPTUS Pharmaceutical Co., Ltd. engages in the manufacture and sale of ophthalmic products. The company is headquartered in Cheongju, Chungcheongbuk-Do and currently employs 171 full-time employees. The company went IPO on 2010-12-03. The firm is primarily engaged in the manufacture and sale of eye drops and ophthalmic preparations such as dry eye treatment agents, conjunctivitis treatment agents, anti-inflammatory medication agents, glaucoma treatment agents and others.
See Also
What is Optus Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-39B
KRW
Based on the financial report for Dec 31, 2025, Optus Pharmaceutical Co Ltd's Cost of Revenue amounts to -39B KRW.
What is Optus Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-10%
Over the last year, the Cost of Revenue growth was -5%. The average annual Cost of Revenue growth rates for Optus Pharmaceutical Co Ltd have been -13% over the past three years , -12% over the past five years , and -10% over the past ten years .
